Examkin

Question

Difficulty: HardMonitoring and Treatment Evaluation

A 54-year-old woman with severe, seropositive rheumatoid arthritis is evaluated in the rheumatology clinic. She continues to experience active synovitis in multiple metacarpophalangeal and proximal interphalangeal joints despite a 6-month trial of optimized methotrexate and a subsequent 4-month trial of etanercept. The physician decides to initiate intravenous tocilizumab. Her medical history is otherwise unremarkable. Baseline screening for latent tuberculosis and viral hepatitis is negative. Which of the following laboratory evaluations are required as part of the specific baseline and ongoing monitoring for this pharmacotherapy? (Select all that apply)

  1. Assessment of absolute neutrophil count, platelet count, and liver transaminasesAnswer
  2. Measurement of a fasting lipid panel 4 to 8 weeks following treatment initiationAnswer
  3. C
    Baseline and periodic echocardiography to assess left ventricular ejection fraction
  4. D
    Regular measurement of serum drug trough levels to guide subsequent dosing
  5. E
    Serial monitoring of prothrombin time and international normalized ratio (PT/INR)

Answer

The necessary monitoring parameters are the assessment of absolute neutrophil count, platelet count, and liver transaminases, as well as the measurement of a fasting lipid panel 4 to 8 weeks following treatment initiation.
Tocilizumab is a monoclonal antibody directed against the interleukin-6 (IL-6) receptor. IL-6 plays a significant role in lipid metabolism, and its inhibition frequently leads to elevated total cholesterol, LDL, and triglycerides. Therefore, a fasting lipid panel is required 4 to 8 weeks after starting therapy and periodically thereafter to determine if lipid-lowering therapy is necessary. Furthermore, tocilizumab can cause dose-dependent neutropenia, thrombocytopenia, and elevated hepatic transaminases. Complete blood counts (to assess absolute neutrophil count and platelets) and liver function tests must be monitored at baseline and routinely (e.g., every 4 to 8 weeks) during ongoing therapy to safely guide dosing.

Step-by-Step Solution

1
Identify the initiated medication and its mechanism of action.
The medication is tocilizumab, which is an interleukin-6 (IL-6) receptor antagonist.
Understanding the pharmacologic mechanism is required to predict adverse effects and required monitoring.
2
Recall the unique adverse effect profile associated with IL-6 inhibition.
IL-6 inhibition is uniquely associated with dyslipidemia, neutropenia, thrombocytopenia, and hepatotoxicity.
Targeted biologic therapies have specific, mechanism-based adverse event profiles distinct from conventional immunosuppressants.
3
Select the laboratory tests that directly monitor for these specific adverse effects.
A fasting lipid panel, complete blood count (for ANC and platelets), and liver function tests are necessary.
Guideline-concordant care requires vigilant surveillance of these specific parameters to ensure patient safety and guide potential dose adjustments or statin initiation.

Key Concept

Monitoring parameters for interleukin-6 (IL-6) receptor antagonists (e.g., tocilizumab) include baseline and ongoing complete blood counts, liver transaminases, and fasting lipid panels.
Rate this question

Topics

Monitoring and Treatment Evaluation

More questions from this topic